Standard Usage and Dosage Guidelines for Teritusumab and Teritusumab

Teritusumab (Teclistamab-cqyv) is a prescription drug and should only be used under the supervision of a physician. The drug is administered via subcutaneous injection (Subcutaneous Injection), which is recommended to be administered by professionals in medical institutions. The standard protocol includes an "increasing dose phase" and a "maintenance treatment phase". This phased design aims to reduce the risk of immune activation and ensure safety.

In the ascending dose phase, patients received an initial dose of 0.06 mg/kg on day (increasing dose 1), then 0.3 mg/kg (increasing dose 2) on day 4, and the official treatment dose of 1.5 mg/kg began on day 7. All patients should be observed in the hospital for at least 48 hours after each injection in the escalating dose phase to prevent severe immune reactions. Physicians can adjust the interval of 2–4 days between increasing doses, up to a maximum of 7 days, to provide flexibility based on individual tolerance.

During the maintenance phase, give 1.5 mg/kg subcutaneously every week If patients achieve and maintain complete remission or better after six months of continuous treatment, the dosing frequency can be adjusted to once every two weeks to reduce immune-related burden and life disruption.

During treatment, the patient's clinical status and laboratory indicators should be closely monitored, especially white blood cell count, liver and kidney function, and infection risk. For patients who develop cytokine release syndrome (CRS) or immune-related neurotoxic reactions, medication should be temporarily suspended and intervention should be performed, and then resumed after symptoms improve.

It should be noted that teritusumab is not an oral drug and cannot be self-administered. Any dosage adjustments or interruptions should be made under the guidance of a doctor. Its treatment principle is to "gradually activate the immune system and maintain the balance of immune killing", which makes it one of the modern models of precision treatment for multiple myeloma (MM).

Reference materials:https://www.tecvayli.com/